Sign In
Buy BBIO
$80.09
-2.05 (-2.50%)
At Close: Jul 31, 2026
1 Top Wall Street Analyst Thinks This Stock Could Soar 95% Over the Next 12 Months. Here's Why I Agree.
05:55am, Sunday, 02'nd Aug 2026
Additional FDA decisions could unlock new growth opportunities. Revenue is expected to nearly double this year.
BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy?
11:06am, Tuesday, 28'th Jul 2026
BridgeBio Pharma (BBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Affinity Asset Advisors LLC Has $11.14 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO
04:05am, Saturday, 25'th Jul 2026
Affinity Asset Advisors LLC cut its stake in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 53.1% during the undefined quarter, according to the company in its most recent disclosure with the Secu
California Public Employees Retirement System Grows Stock Holdings in BridgeBio Pharma, Inc. $BBIO
04:11am, Friday, 24'th Jul 2026
California Public Employees Retirement System raised its holdings in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 21.9% in the undefined quarter, according to its most recent 13F filing with the SEC. The
FDA Accepts BridgeBio's Filing for Rare Genetic Disease Drug
02:16pm, Thursday, 23'rd Jul 2026
BBIO's FDA filing for encaleret in ADH1 has been accepted, moving the rare disease candidate closer to a decision expected by May 2027.
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
07:30am, Wednesday, 22'nd Jul 2026
- PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1 , representing a potential blockb
Allspring Global Investments Holdings LLC Sells 104,864 Shares of BridgeBio Pharma, Inc. $BBIO
03:11am, Saturday, 18'th Jul 2026
Allspring Global Investments Holdings LLC cut its holdings in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 10.5% during the undefined quarter, according to its most recent disclosure with the Securities a
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
12:25pm, Monday, 13'th Jul 2026
When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset e
BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play
09:55am, Sunday, 12'th Jul 2026
BridgeBio Pharma (BBIO) remains a "Strong Buy," driven by regulatory approvals, robust pipeline progress, and significant commercial momentum for Attruby in ATTR-CM. Company has achieved U.S. and inte
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 10'th Jul 2026
PALO ALTO, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genet
How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High
01:25pm, Friday, 10'th Jul 2026
BridgeBio Pharma hit a 52-week high after a rival's phase III setback boosts confidence in Attruby's competitive position in ATTR-CM.
BridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?
06:36am, Friday, 10'th Jul 2026
BridgeBio Pharma (BBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength dow
BridgeBio Stock Taps Rare Disease Trends and New Diagnosis Growth
01:31pm, Wednesday, 08'th Jul 2026
BBIO builds on Attruby's launch as rising rare disease diagnoses and late-stage pipeline candidates set up multiple potential U.S. launches.
BridgeBio Stock Outlook Hinges on Attruby & New Drug Catalysts
01:25pm, Wednesday, 08'th Jul 2026
BBIO's outlook hinges on Attruby growth, upcoming drug launch catalysts and execution as it seeks to diversify beyond its lone marketed therapy.
Is BBIO Stock a Buy Now or Too Expensive for the Risk Ahead
01:25pm, Wednesday, 08'th Jul 2026
BridgeBio Pharma BBIO has become a harder stock to judge after its sharp rare-disease run. Attruby is ramping quickly, yet the valuation already assumes a good deal of future success.
